RT Journal Article
SR Electronic
T1 Helicobacter pylori: new developments and treatments
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 1565
OP 1574
VO 156
IS 11
A1 SJO. Veldhuyzen van Zanten
A1 P. M. Sherman
A1 R. H. Hunt
YR 1997
UL http://www.cmaj.ca/content/156/11/1565.abstract
AB The authors highlight new developments in research on Helicobacter pylori. There is now consensus that all patients with newly diagnosed or recurrent duodenal or gastric ulcers who have a positive test result for H. pylori should be treated for the infection. Patients presenting with complications of ulcers, such as bleeding, should also be treated. H. pylori has recently been classified as a definite human carcinogen by the International Agency for Research on Cancer. In treatment, new combination regimens, consisting of 3 or 4 different drugs, cure the infection in more than 80% of patients. Currently, the best combinations are: (1) omeprazole (or another proton-pump inhibitor), clarithromycin and metronidazole, (2) omeprazole (or another proton-pump inhibitor), clarithromycin and amoxicillin, (3) bismuth subsalicylate, tetracycline and metronidazole, and (4) omeprazole, bismuth subsalicylate, tetracycline and metronidazole.